Skip to content
Immunexpress
  • Home
  • About Us
    • About Immunexpress
    • Executive Team
    • Board Of Directors
    • Careers
  • About Sepsis
    • The Sepsis Problem
    • Partnership with Sepsis Alliance
    • External Resources
  • About SeptiCyte®
    • SeptiCyte™ RAPID
    • Host Response
    • SeptiCyte™ LAB
  • Validation
    • Clinical Validation
    • Publications
    • Collaborators
  • Newsroom
  • Contact Us
Immunexpress
  • Home
  • About Us
    • About Immunexpress
    • Executive Team
    • Board Of Directors
    • Careers
  • About Sepsis
    • The Sepsis Problem
    • Partnership with Sepsis Alliance
    • External Resources
  • About SeptiCyte®
    • SeptiCyte™ RAPID
    • Host Response
    • SeptiCyte™ LAB
  • Validation
    • Clinical Validation
    • Publications
    • Collaborators
  • Newsroom
  • Contact Us

Archive for November 2018

Sepset’s Sepsis Signature

By Helene Kuhn | November 16, 2018

BioCentury Senior Writer Michael Leviten discusses gene expression tests that could speed up diagnosis of sepsis.

Read More

About Us

Immunexpress is a privately-owned group of companies developing and commercializing revolutionary molecular diagnostics to aid clinicians in managing patients with, or suspected of, sepsis through analysis of molecular blood biomarkers from a patient’s immune system (the ‘host response’).

Additional Resources

Newsroom

Contact Us

Privacy policy

 

Tweets by @Immunexpress

© 2023 Immunexpress Inc. — all Rights Reserved.
425 Pontius Avenue North, Suite 470, Seattle, WA 98109 USA
+1 206.858.6436 – info@immunexpress.com

Scroll To Top